article inpress Klara Klein author Litty Johnson author Ramona Rîca author Mirza Sarcevic author Gabriele Carta author Saskia Seiser author Adelheid Elbe-Bürger author Freyja Langer author 3C1BE782-F248-11E8-B48F-1D18A9856A87 Nowras Rahhal author Christoph Rademacher author Robert Wawrzinek author Federica Quattrone author Florian Sparber author PreCl department Despite the success of mRNA therapeutics, challenges remain in optimizing immune responses and minimizing side effects. Cell-specific antigen delivery may help reduce required doses and improve vaccine efficacy. In this study, we report on a targeted delivery system for mRNA to a specific subset of skin-resident antigen-presenting cells: Langerhans cells. By functionalizing lipid nanoparticles with a langerin-specific glycomimetic ligand, we achieve selective mRNA delivery to both murine and human primary Langerhans cells with minimal off-target uptake, at the same time resulting in significantly increased mRNA translation. This targeted mRNA delivery not only enhances antigen presentation and T-cell responses but also enables dose-sparing and superior antitumor immunity compared with conventional immunization in a B16-OVA tumor model. Importantly, our platform’s high compatibility with various lipid nanoparticle formulations offers a flexible and precise tool for skin-directed mRNA delivery. Elsevier2026 eng 0022-202X 1523-174710.1016/j.jid.2026.03.026 Klein, K., Johnson, L., Rîca, R., Sarcevic, M., Carta, G., Seiser, S., … Sparber, F. (n.d.). Langerhans cell–targeted mRNA delivery: A strategy for dose-sparing and enhanced antitumor immunity. <i>Journal of Investigative Dermatology</i>. Elsevier. <a href="https://doi.org/10.1016/j.jid.2026.03.026">https://doi.org/10.1016/j.jid.2026.03.026</a> K. Klein, L. Johnson, R. Rîca, M. Sarcevic, G. Carta, S. Seiser, A. Elbe-Bürger, F. Langer, N. Rahhal, C. Rademacher, R. Wawrzinek, F. Quattrone, F. Sparber, Journal of Investigative Dermatology (n.d.). Klein K, Johnson L, Rîca R, et al. Langerhans cell–targeted mRNA delivery: A strategy for dose-sparing and enhanced antitumor immunity. <i>Journal of Investigative Dermatology</i>. doi:<a href="https://doi.org/10.1016/j.jid.2026.03.026">10.1016/j.jid.2026.03.026</a> Klein, Klara, Litty Johnson, Ramona Rîca, Mirza Sarcevic, Gabriele Carta, Saskia Seiser, Adelheid Elbe-Bürger, et al. “Langerhans Cell–Targeted MRNA Delivery: A Strategy for Dose-Sparing and Enhanced Antitumor Immunity.” <i>Journal of Investigative Dermatology</i>. Elsevier, n.d. <a href="https://doi.org/10.1016/j.jid.2026.03.026">https://doi.org/10.1016/j.jid.2026.03.026</a>. K. Klein <i>et al.</i>, “Langerhans cell–targeted mRNA delivery: A strategy for dose-sparing and enhanced antitumor immunity,” <i>Journal of Investigative Dermatology</i>. Elsevier. Klein, Klara, et al. “Langerhans Cell–Targeted MRNA Delivery: A Strategy for Dose-Sparing and Enhanced Antitumor Immunity.” <i>Journal of Investigative Dermatology</i>, Elsevier, doi:<a href="https://doi.org/10.1016/j.jid.2026.03.026">10.1016/j.jid.2026.03.026</a>. Klein K, Johnson L, Rîca R, Sarcevic M, Carta G, Seiser S, Elbe-Bürger A, Langer F, Rahhal N, Rademacher C, Wawrzinek R, Quattrone F, Sparber F. Langerhans cell–targeted mRNA delivery: A strategy for dose-sparing and enhanced antitumor immunity. Journal of Investigative Dermatology. 218482026-05-10T22:02:16Z2026-05-11T06:07:32Z